Abstract
Background In Uganda, fertility rates and adult HIV prevalence are high, and many women conceive with partners living with HIV. Oral pre-exposure prophylaxis (PrEP) reduces HIV acquisition risk for women and, therefore, infants. We conducted a longitudinal cohort study in Uganda to evaluate oral PrEP uptake and adherence as part of HIV prevention in the context of reproductive goals for women (i.e., safer conception care).
Methods We enrolled HIV-negative women with personal or partner plans for pregnancy with a partner living, or thought to be living, with HIV (2017-2020) to evaluate the impact of the Healthy Families intervention on PrEP use. Quarterly study visits through 9 months included HIV and pregnancy testing, and safer conception counseling. PrEP was provided to women in electronic pillboxes as the primary adherence measure (categorized as “high” with pillbox openings on >80% of days). Enrollment questionnaires assessed factors associated with PrEP use. Plasma tenofovir (TFV) and intraerythrocytic TFV-diphosphate (TFV-DP) concentrations were determined at each visit for women who acquired HIV during follow-up and a randomly selected subset of those who did not. Women who became pregnant were initially exited from the cohort by design; from April 2019, women with incident pregnancy remained in the study with quarterly follow-up until pregnancy outcome. Primary outcomes included (1) PrEP uptake (proportion of enrolled women who initiated PrEP) and (2) PrEP adherence (proportion of days with electronic pillbox openings during the first 3 months following PrEP initiation). We used univariable and multivariable-adjusted linear regression to evaluate baseline predictors of mean adherence over 3 months. We also assessed mean monthly adherence over 9 months of follow-up and during pregnancy.
Results We enrolled 131 women with a mean age of 28.7 years (95% CI: 27.8-29.5). Ninety-seven (74%) reported a partner with HIV and 79 (60%) reported condomless sex at last encounter. Most women (N=118; 90%) initiated PrEP. Mean electronic adherence during the 3 months following initiation was 87% (95% CI: 83%, 90%); most (85%) had adherence >80%. No covariates were associated with 3-month pill-taking behavior. Plasma TFV concentrations were >40ng/mL among 66%, 56%, and 45% at months 3, 6, and 9, respectively. TFV-DP concentrations were >600 fmol/punch among 47%, 41%, and 45% of women at months 3, 6, and 9. We observed 53 pregnancies among 131 women with 848 person-months of follow-up (annualized incidence 75% [95% CI: 57%, 98%]) and one HIV-seroconversion in a non-pregnant woman accessing PrEP. Mean pillcap adherence for PrEP users with pregnancy follow-up (N=17) was 98% (95% CI: 97%, 99%).
Conclusions Women in Uganda with PrEP indications and planning for pregnancy chose to use PrEP. By electronic pillcap, most were able to sustain high adherence to daily oral PrEP prior to and during pregnancy. Differences in adherence measures highlight challenges with adherence assessment and serial measures suggest 41-66% of women took sufficient periconception PrEP to prevent HIV. These data suggest that women planning for and with pregnancy should be prioritized for PrEP implementation, particularly in settings with high fertility rates and generalized HIV epidemics.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: Gilead Sciences provided study drug. LTM and CWH have received clinical research funding from Gilead Sciences. PLA has received consultant fees from Merck, ViiV, and Gilead and research support from Gilead. JEH has received consultant fees from Merck and Natera.
Clinical Trial
ClinicalTrials.gov Identifier: NCT03832530
Funding Statement
Gilead Sciences provided study drug and reviewed the final manuscript. Funding: Doris Duke Clinician Scientist Development Award (LTM) AMC 21 UAB (LTM)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approvals were secured from the Partners HealthCare Institutional Review Board (IRB), Mbarara University of Science and Technology Research Ethics Committee, and University of Alabama at Birmingham IRB. Regulatory approvals were also secured from Uganda’s Office of the President and the National Council of Science and Technology.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data will be available in the Harvard Dataverse database after acceptance for publication.
